Skip to Main text


Press Release 2019


Launch of Bisono™ Tape 2mg, a Transdermal Patch Containing a β1 Blocker

Nitto Denko Corporation (Head Office: Osaka, Japan; President, CEO & COO: Hideo Takasaki, “Nitto”) announced that Bisono™ Tape 2mg (non-proprietary name: bisoprolol), transdermal patches containing a β1 blocker that were co-developed with Toa Eiyo Ltd. (President: Atsuo Takahashi, Ph.D., “Toa Eiyo”), has been launched today by Toa Eiyo and Astellas Pharma Inc. (President and CEO: Kenji Yasukawa). 

Jointly developed by Nitto and Toa Eiyo, Bisono™ Tape is the world’s first transdermal patch containing a β1 blocker. BisonoⓇ Tape 4mg and BisonoⓇ Tape 8mg were launched in September 2013 as medication for essential hypertension (mild to moderate cases). Furthermore, additional approval for efficacy in atrial fibrillation was received in January 2019 and the formulation was improved for better water-resistant adhesion.

The new Bisono™ Tape 2mg with efficacy in atrial fibrillation* will enable even finer dose adjustments in atrial fibrillation treatment.

With this additional launch, Bisono™ Tape 2mg, 4mg, and 8mg will help patients who suffer from atrial fibrillation and have difficulties in swallowing oral medication by improving medication adherence and thereby supporting treatment continuation for this group of patients.

*See the table below regarding the efficacy of Bisono™ Tape.
EfficacyBisono™ Tape 2 mgBisono™ Tape 4 mgBisono™ Tape 8 mg
Essential hypertension
(Mild to moderate cases)
Atrial fibrillation
○: Efficacy obtained

Drug product photograph

Launch of Bisono™ Tape 2 mg, a Transdermal Patch Ccontaining a β1 Blocker

Contact Us

For any inquiries about this press release.

Business Hours (EST)
8:00 a.m.-5:30 p.m.(Except for Sat, Sun, and Holidays)

Here is the information at the release day. This information may be different from the information at other medias. Please be forewarned.

Related Information

Back to Page Top